Abstract
Lymphoma has been reported to worsen the prognosis of COVID-19 partly because it disturbs the normal production of antibodies. We treated a man with mantle cell lymphoma treated with rituximab, who developed severe COVID-19 with viral shedding that lasted for 78 days. He stayed in the intensive care unit for 28 days and did not respond to any treatment against COVID-19. His increased oxygen demand at rest eventually resolved despite the absence of anti-SARS-CoV-2-IgG. This case illustrates that recovery from COVID-19 can occur without antibody production, and that even patients with an inability to produce antibodies can recover from severe COVID-19. It also illustrates that lymphoma patients who develop severe COVID-19 while on rituximab therapy can recover from a prolonged viral shedding state if the acute lung injury can be overcome.
Keywords: Antibody; COVID-19; Immunocompromised state; Lymphoma; Rituximab; SARS-CoV-2.
【저자키워드】 COVID-19, SARS-CoV-2, antibody, rituximab, lymphoma, immunocompromised state, 【초록키워드】 Treatment, antibodies, SARS-CoV-2, therapy, intensive care, severe COVID-19, Prognosis, viral shedding, oxygen, acute lung injury, Patient, prolonged viral shedding, antibody production, develop, reported, treated, absence, occur, overcome, respond, resolved, mantle cell, 【제목키워드】 anti-SARS-CoV-2 antibody, Evidence, treated, mantle cell,